Results 161 to 170 of about 702,558 (291)

Harnessing ferroptosis from multilayer defense networks to nanoplatforms for specific cancer therapy

open access: yesBMEMat, EarlyView.
Nanomaterials target metabolically‐regulated ferroptosis for cancer therapy. Iron‐based or alternative nanoplatforms integrate ferroptosis with chemotherapy, immunotherapy, or radiotherapy. They enable stimulus‐responsive therapies (photothermal, photodynamic, sonodynamic) activated by near‐infrared, light, or ultrasound, achieving potent synergistic ...
Xinyue Xu   +5 more
wiley   +1 more source

M5 positive allosteric modulation alleviates parkinsonian motor deficits. [PDF]

open access: yesPLoS One
Chambers NE   +5 more
europepmc   +1 more source

From Caffeine to Aspirin: Everyday Molecules as Triggers for Genetically Encoded Proximity Systems

open access: yesChemistry – A European Journal, EarlyView.
This Perspective article highlights how familiar dietary ingredients and over‐the‐counter (OTC) drugs (such as caffeine and its metabolites, SA, and aspirin) can be repurposed as clinically translatable chemical triggers for genetically encoded proximity systems.
Mingguang Cui   +5 more
wiley   +1 more source

Protein-Driven Copper Redox Regulation: Uncovering the Role of Disulphide Bonds and Allosteric Modulation. [PDF]

open access: yesAngew Chem Int Ed Engl
Sternke-Hoffmann R   +9 more
europepmc   +1 more source

Microtubule Destabilizing Kinesins: A Historical Perspective and Thoughts for the Future

open access: yesCytoskeleton, EarlyView.
ABSTRACT The microtubule cytoskeleton plays critical roles in multiple cellular processes such as mitotic spindle assembly and chromosome segregation. Cells contain a number of microtubule‐associated proteins that regulate microtubule dynamics both temporally and spatially in cells. The microtubule depolymerizing kinesins include members of the Kinesin‐
Claire E. Walczak
wiley   +1 more source

Molecular determinants of allosteric modulation of protein disulfide isomerase by small-molecule b'-ligands. [PDF]

open access: yesRedox Biol
Ponzar N   +6 more
europepmc   +1 more source

Considerations for drug trials in hypertrophic cardiomyopathy

open access: yesESC Heart Failure, Volume 12, Issue 2, Page 1095-1112, April 2025.
Abstract Hypertrophic cardiomyopathy (HCM) is a heterogeneous condition with potentially serious manifestations. Management has traditionally comprised therapies to palliate symptoms and implantable cardioverter‐defibrillators to prevent sudden cardiac death. The need for disease‐modifying therapies has been recognized for decades.
John P. Farrant   +17 more
wiley   +1 more source

Selective positive allosteric modulation of β<sub>2</sub>AR using antibody fragments targeting the third intracellular loop. [PDF]

open access: yesNat Commun
Sánchez Rivas EJ   +8 more
europepmc   +1 more source

Home - About - Disclaimer - Privacy